U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C6H6O2
Molecular Weight 110.1106
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Resorcinol

SMILES

OC1=CC(O)=CC=C1

InChI

InChIKey=GHMLBKRAJCXXBS-UHFFFAOYSA-N
InChI=1S/C6H6O2/c7-5-2-1-3-6(8)4-5/h1-4,7-8H

HIDE SMILES / InChI

Molecular Formula C6H6O2
Molecular Weight 110.1106
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/mtm/resorcinol-topical.html and http://www.fda.gov/downloads/Drugs/.../Guidances/UCM259744.pdf

Resorcinol is a benzenediol. Resorcinol is commonly used in hair dyes and acne medication. Resorcinol works by breaking down rough, scaly, or hardened skin. Resorcinol also disinfects the skin to help fight infection. Resorcinol topical (for the skin) is used to treat pain and itching caused by minor cuts and scrapes, burns, insect bites, poison ivy, sunburn, or other skin irritations. Resorcinol topical is also used to treat acne, eczema, psoriasis, seborrhea, corns, calluses, warts, and other skin disorders. Resorcinol is included in the FDA final rule list of all permitted active ingredients for OTC topical acne products. Permitted combination active ingredient product - Resorcinol in 2 percent concentration in combination with sulfur in concentrations of between 3 and 8 percent. In oxidative hair dyes, resorcinol is regulated to 5% or below in practice, however, many manufacturers limit the level of free resorcinol in oxidative hair dyes to 1.25%. Resorcinol is limited to 0.5% in shampoos and hair lotions. Resorcinol is usually present in anti-acne preparations at a maximum concentration of 2%. The concentration of resorcinol can be much higher in peels, in some cases around 50%. Jessner’s solution (resorcinol in ethyl alcohol, 14% w/v; lactic acid, 14%; and salicylic acid, 14%) is commonly used in chemical peeling. A specialized medical use of resorcinol is in biological glues (gelatin–resorcinol–formaldehyde glue) for cardiovascular surgery, in particular aortic operations.

Originator

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P14650
Gene ID: NA
Gene Symbol: Tpo
Target Organism: Rattus norvegicus (Rat)
253.0 µM [IC50]
Target ID: Prostaglandin E2 synthesis
10.0 µM [IC50]
180.0 µM [IC50]
Target ID: Leukotriene E4 biosynthetic process
902.0 µM [IC50]
Target ID: Thromboxane B2 biosynthetic process
25.0 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Resinol

Approved Use

Resorcinol topical (for the skin) is used to treat pain and itching caused by minor cuts and scrapes, burns, insect bites, poison ivy, sunburn, or other skin irritations. Resorcinol topical is also used to treat acne, eczema, psoriasis, seborrhea, corns, calluses, warts, and other skin disorders.

Launch Date

1991
Primary
Resinol

Approved Use

Resorcinol topical (for the skin) is used to treat pain and itching caused by minor cuts and scrapes, burns, insect bites, poison ivy, sunburn, or other skin irritations. Resorcinol topical is also used to treat acne, eczema, psoriasis, seborrhea, corns, calluses, warts, and other skin disorders.

Launch Date

1989
Doses

Doses

DosePopulationAdverse events​
3 % 1 times / day multiple, topical
Recommended
Dose: 3 %, 1 times / day
Route: topical
Route: multiple
Dose: 3 %, 1 times / day
Sources:
unhealthy, 14-29
Health Status: unhealthy
Age Group: 14-29
Sex: M+F
Sources:
Disc. AE: Application site discomfort...
AEs leading to
discontinuation/dose reduction:
Application site discomfort (3.13%)
Sources:
30 mg/kg 1 times / day multiple, topical
Overdose
Dose: 30 mg/kg, 1 times / day
Route: topical
Route: multiple
Dose: 30 mg/kg, 1 times / day
Sources:
unhealthy
Other AEs: Hypothyroidism...
AEs

AEs

AESignificanceDosePopulation
Application site discomfort 3.13%
Disc. AE
3 % 1 times / day multiple, topical
Recommended
Dose: 3 %, 1 times / day
Route: topical
Route: multiple
Dose: 3 %, 1 times / day
Sources:
unhealthy, 14-29
Health Status: unhealthy
Age Group: 14-29
Sex: M+F
Sources:
Hypothyroidism
30 mg/kg 1 times / day multiple, topical
Overdose
Dose: 30 mg/kg, 1 times / day
Route: topical
Route: multiple
Dose: 30 mg/kg, 1 times / day
Sources:
unhealthy
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Purification and characterization of 2,6-dihydroxybenzoate decarboxylase reversibly catalyzing nonoxidative decarboxylation.
2004-06
Diastereoselective dearomatization of resorcinols directed by a lactic acid tether: unprecedented enantioselective access to p-quinols.
2004-05-13
Immunopathogenesis of experimental ulcerative colitis is mediated by eosinophil peroxidase.
2004-05-01
Development of non-electrophoretic assay method for DNA ligases and its application to screening of chemical inhibitors of DNA ligase I.
2004-04-30
Decomposition of aqueous diphenyloxide by ozonolysis and by combined gamma-ray-ozone processing.
2004-03-17
A mechanistic study on the nuclease activities of some hydroxystilbenes.
2004-03-01
Laparoscopic partial nephrectomy using holmium laser in a porcine model.
2004-02-21
Preparation of tripyrrane analogues from resorcinol and 2-methylresorcinol for applications in the synthesis of new benziporphyrin systems.
2004-01-21
[Glycine determination according to the European Pharmacopoeia].
2004-01
New efficient procedure for the use of diethoxyphosphoryl as a protecting group in the synthesis of polyazamacrocycles. Preparation of polyazacyclophanes derived from resorcinol.
2003-12-26
Biosynthesis of 5-alkylresorcinol in rice: incorporation of a putative fatty acid unit in the 5-alkylresorcinol carbon chain.
2003-12
Single-crystal-to-single-crystal topochemical polymerizations of a terminal diacetylene: two remarkable transformations give the same conjugated polymer.
2003-10-15
Effect of some process parameters in enzymatic dyeing of wool.
2003-10
Substituent effects in the BF3-mediated acylation of phenols with cinnamic acids.
2003-10
Rapid stimulation of free glucuronate formation by non-glucuronidable xenobiotics in isolated rat hepatocytes.
2003-09-19
A graphitized-carbon monolithic column.
2003-09-15
Non-enzymatic interaction of reaction products and substrates in peroxidase catalysis.
2003-09
A new variant activator involved in the degradation of phenolic compounds from a strain of Pseudomonas putida.
2003-08-15
Elucidation of the biosynthetic pathway of the allelochemical sorgoleone using retrobiosynthetic NMR analysis.
2003-08-01
Determination of phloroglucinol in human plasma by high-performance liquid chromatography-mass spectrometry.
2003-07-25
Simple mimetics of a nuclear localization signal (NLS).
2003-07-10
Resorcinol-formaldehyde resin "Russian Red" endodontic therapy.
2003-07
ABC transporters of the wheat pathogen Mycosphaerella graminicola function as protectants against biotic and xenobiotic toxic compounds.
2003-07
Glucuronuria in the koala.
2003-06
Prenylated flavonoids from the roots of Sophora flavescens with tyrosinase inhibitory activity.
2003-06
Multivalent drug design. Synthesis and in vitro analysis of an array of vancomycin dimers.
2003-05-28
More advice for chronic skin conditions.
2003-05
Downregulation of NF-kappaB activation in human keratinocytes by melanogenic inhibitors.
2003-05
Kinetics of anaerobic biodegradation of resorcinol catechol and hydroquinone in upflow fixed film-fixed bed reactors.
2003-05
The effect of pH on the decomposition of hydrophenols in aqueous solutions by ultraviolet direct photolysis and the ultraviolet-hydrogen peroxide process.
2003-04-10
Inhibition of serotonin re-uptake by licorice constituents.
2003-04
The use of thermal lensing for the determination of pyrogens.
2003-04
[Influence of the mixed disinfectant of ClO2 and Cl2 on formation of chloroform].
2003-03
Quantitative structure-activity relationships for estrogen receptor binding affinity of phenolic chemicals.
2003-03
Determination of major phenolic compounds in water by reversed-phase liquid chromatography after pre-column derivatization with benzoyl chloride.
2003-02-21
[Study on the spectral properties of caffeic acid and its derivatives].
2003-02
Investigation of antioxidant and catalytic properties of some biologically active substances by voltammetry.
2003-02
Method for analysis of tannic acid and its metabolites in biological samples: application to tannic acid metabolism in the rat.
2003-01-01
The effect of endodontic solutions on resorcinol-formalin paste.
2003-01
Biotransformation of the mycotoxin, zearalenone, to a non-estrogenic compound by a fungal strain of Clonostachys sp.
2002-12
Vibrational analysis of substituted phenols: part I. Vibrational spectra, normal coordinate analysis and transferability of force constants of some formyl-, methoxy-, formylmethoxy-, methyl- and halogeno-phenols.
2002-12
Adsorption and detection of some phenolic compounds by rice husk ash of Kenyan origin.
2002-12
Attachment of alkyltrichlorosilanes to the terminal 3,5-dihydroxyphenyl moiety of a self-assembled thiol monolayer on gold.
2002-11-15
[Application of artificial neural network to simultaneous spectro-fluorimetric determination of phenol and resorcinol].
2002-10
Structural and energetic aspects of the protonation of phenol, catechol, resorcinol, and hydroquinone.
2002-07-02
Enzymological aspects of bioconversion of m-dinitrobenzene.
2002-07
[Resorcinol-spectrophotometric method for the determination of fructose in mustard leaf's amylose].
2002-06
The toxicity and fate of phenolic pollutants in the contaminated soils associated with the oil-shale industry.
2002
[Determination of salicylic acid, resorcinol and chloramphenicol in junlieping tincture by reversed-phase high performance liquid chromatography].
2001-07
Metabolism of resorcinylic compounds by bacteria: orcinol pathway in Pseudomonas putida.
1976-03
Patents

Sample Use Guides

Resorcinol topical 2% ointment: Apply to affected area not more than 3 to 4 times daily.
Route of Administration: Topical
0.3 umol/l of Resorcinol caused a 50% inhibition of thyroid peroxidase
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:33:39 GMT 2025
Edited
by admin
on Mon Mar 31 17:33:39 GMT 2025
Record UNII
YUL4LO94HK
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RESORCINUM
HPUS  
Preferred Name English
Resorcinol
EP   FHFI   HSDB   INCI   MART.   MI   USP   USP-RS   VANDF   WHO-DD  
INCI  
Official Name English
C.I. OXIDATION BASE 31
Common Name English
NSC-1571
Code English
M-DIHYDROXYBENZENE
Systematic Name English
RESORCINOL [USP MONOGRAPH]
Common Name English
FLUORESCEIN IMPURITY A [EP IMPURITY]
Common Name English
FEMA NO. 3589
Code English
FLUORESCEIN SODIUM IMPURITY A [EP IMPURITY]
Common Name English
RESORCINUM [HPUS]
Common Name English
RESORCINOL [EP MONOGRAPH]
Common Name English
RESORCIN [JAN]
Common Name English
RESORCINOL [VANDF]
Common Name English
RESORCINOL [HSDB]
Common Name English
RESORCINOL [FHFI]
Common Name English
1,3-BENZENEDIOL
Systematic Name English
RESORCIN
JAN  
Systematic Name English
HEXYLRESORCINOL IMPURITY B [EP IMPURITY]
Common Name English
RESORCINOL [MART.]
Common Name English
RESORCINOL [IARC]
Common Name English
RESORCINOL [MI]
Common Name English
BENZENE-1,3-DIOL
Common Name English
Resorcinol [WHO-DD]
Common Name English
C.I.-76505
Code English
1,3-DIHYDROXYBENZENE
Systematic Name English
RESORCINOL [USP-RS]
Common Name English
Classification Tree Code System Code
WHO-VATC QS01AX06
Created by admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
NCI_THESAURUS C28394
Created by admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
WHO-ATC D10AX02
Created by admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
CFR 21 CFR 333.310
Created by admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
WHO-ATC S01AX06
Created by admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
CFR 21 CFR 333.320
Created by admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
WHO-VATC QD10AX02
Created by admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
JECFA EVALUATION RESORCINOL
Created by admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
CFR 21 CFR 346.20
Created by admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
Code System Code Type Description
DRUG BANK
DB11085
Created by admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
PRIMARY
RS_ITEM_NUM
1602003
Created by admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
PRIMARY
FDA UNII
YUL4LO94HK
Created by admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
PRIMARY
SMS_ID
100000078653
Created by admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
PRIMARY
NSC
1571
Created by admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
PRIMARY
PUBCHEM
5054
Created by admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
PRIMARY
JECFA MONOGRAPH
590
Created by admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
PRIMARY
WIKIPEDIA
RESORCINOL
Created by admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
PRIMARY
MESH
C031389
Created by admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
PRIMARY
NCI_THESAURUS
C77056
Created by admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
PRIMARY
ChEMBL
CHEMBL24147
Created by admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
PRIMARY
RXCUI
35382
Created by admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
PRIMARY RxNorm
CHEBI
27810
Created by admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
PRIMARY
MERCK INDEX
m9546
Created by admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
PRIMARY Merck Index
DAILYMED
YUL4LO94HK
Created by admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
PRIMARY
DRUG CENTRAL
3524
Created by admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
PRIMARY
EVMPD
SUB15120MIG
Created by admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
PRIMARY
EPA CompTox
DTXSID2021238
Created by admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
PRIMARY
ECHA (EC/EINECS)
203-585-2
Created by admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
PRIMARY
HSDB
722
Created by admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
PRIMARY
CAS
108-46-3
Created by admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY